Stay updated with breaking news from Peter Maag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...
Operator: Good day, everyone, and welcome to today's CareDx Inc. Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
The FDA has granted clearance to Kyverna Therapeutics’ investigational new drug application enabling initiation of the Phase I/II KYSA-5 trial of KYV-101.
StockNews.com started coverage on shares of CareDx (NASDAQ:CDNA – Free Report) in a research report sent to investors on Thursday. The firm issued a hold rating on the stock. A number of other analysts have also weighed in on the stock. HC Wainwright reiterated a neutral rating on shares of CareDx in a report on […]
CareDx, Inc (NASDAQ:CDNA – Get Free Report) has been assigned an average rating of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among […]